chexia may involve the action of myokines released from skeletal muscle (25) .
In its nonglycosylated state, IL-7 has a predicted molecular mass of 17 kDa, whereas ϳ25 kDa has been reported for the glycosylated protein (28) . IL-7 plays fundamental roles in thymic development and homeostatic maintenance of T and B lymphocytes (1, 48) . A receptor associated with the plasma membrane mediates IL-7 signaling. This receptor (IL-7R) is a heterodimer consisting of the IL-7R␣ chain and the common cytokine ␥-chain (21) . Production of IL-7 has been attributed to the stromal cells in lymphoid organs, mainly the thymus in mice (28) whereas the spleen may be a significant production site in humans (17) . Production of IL-7 is likely to occur at a constant rate, and the amount of circulating IL-7 in vivo may be regulated by IL-7R-mediated binding rather than production (23) . Recent data question this notion by showing that hepatic IL-7 secretion is associated with an acute-phase response in mice promoting enhanced numbers of naive and memory CD4-and CD8-positive T cells (38) . Increased levels of circulating IL-7 levels are observed in T cell lymphopenic patients with human immunodeficiency virus (HIV) infections, bone marrow transplants, and chemotherapy (13) , which may reflect reduced IL-7 clearance or increased release into circulation. In addition, elevated levels of IL-7 have been detected in synovial fluid from patients with rheumatoid arthritis (46) . However, the potential of skeletal muscle cells to produce and secrete IL-7 is unclear.
Human myotubes can be differentiated in vitro from satellite cells, which are skeletal muscle stem cells capable of differentiating from a quiescent state to repair damaged skeletal muscle (14) . Here we studied primary cultures of differentiated human myotubes in vitro and extended our findings in vivo, and we report data indicating that IL-7 is a novel myokine, potentially affecting satellite cells during muscle development.
MATERIALS AND METHODS

Satellite cells and skeletal muscle tissue biopsies.
Primary human satellite cells for in vitro experiments were isolated from muscle biopsies taken from musculus obliquus internus abdominis of healthy kidney donor volunteers aged 28 -53 yr, exhibiting body mass index and fasting plasma concentrations of glucose and insulin within normal ranges. Frozen stocks of fibroblast-free satellite cell cultures were established by the method of Henry et al. (18) with minor modifications. In brief, muscle tissue was dissected in Ham's F-10 medium (Sigma-Aldrich, St. Louis, MO) at 4°C and dissociated by three successive incubations with 0.05% trypsin-EDTA (Sigma-Aldrich). The satellite cells were resuspended in human skeletal growth medium [SkGM; supplemented with 10 ng/ml EGF, 0.5 mg/ml bovine fetuin, 0.39 g/ml dexamethasone, 0.5 mg/ml BSA, and 50 g/ml gentamicin sulfate (Lonza, Basel, Switzerland)]. Two millimolar Lglutamine, 50 U/ml penicillin, 50 g/ml streptomycin, and 2% fetal calf serum (FCS) were also added (Sigma-Aldrich), but without insulin. After thawing, the satellite cells were grown for 24 h in flasks coated with ECM gel and supplemented with growth medium M1: DMEM (5.5 mM glucose) containing 10% FCS (vol/vol), 2 mM L-glutamine, 50 U/ml penicillin, and 50 g/ml streptomycin (SigmaAldrich) (14) . Selective satellite cell proliferation was promoted by subculturing cells in SkGM. After three to seven additional passages of subculturing satellite cells were grown to 70 -80% confluence on CellBIND plates or flasks (Corning, Lowell, MA), and differentiation into multinucleated myotubes was initiated on day 0 by changing to growth medium M3, similar to M1 but containing 2% FCS and additionally 25 pM Actrapid insulin (Novo Nordisk, Bagsvaerd, Denmark). Cultures of differentiated myotubes were used for experiments on day 7 after the onset of differentiation. Myotubes were incubated with or without LPS (Sigma-Aldrich) and with or without brefeldin A (BFA, Sigma-Aldrich). Murine C2C12 (ATCC no. CRL-1772) and Sol8 (ATCC no, CRL-2174) myotubes were differentiated for 5-6 days (9, 49) . In vivo data were based on needle biopsies of musculus vastus lateralis obtained by three different insertions under local anesthesia from a subgroup of healthy male subjects (n ϭ 10) participating in an earlier study (37) ; median age was 26 yr (range ϭ 16 yr), and body mass index was 24.5 (10.4) kg/m 2 . Muscle samples were rinsed in saline, divided into smaller pieces, placed in RNAlater (Ambion, Austin, TX), and stored at Ϫ20°C until total RNA was prepared based on a modified version of the single-step method described by Chomczynski and Sacchi (see Ref. 15) . The subjects participated in a strength training program three times per week for a duration of 11 wk (37) . Each workout included one to three sets of leg press, leg extension, leg curl, seated chest press, seated rowing, latissimus pull down, biceps curl, and shoulder press for all subjects. Biopsies were taken at baseline and after 2 and 11 wk of training. All biopsies were obtained with informed consent and approved by the National Committee for Research Ethics, Oslo, Norway.
Analysis of cytokines by Luminex xMAP Multiplex bead array. Cell culture supernatants (1 ml) were aspirated from myotubes grown in 12-well plates and stored at Ϫ20°C. The high-sensitivity Human Cytokine Lincoplex Kit (Millipore, Billerica, MA) was prepared and used according to the manufacturer's protocol. In brief, samples were incubated overnight with microspheres, which were internally dyed with a specific mixture of two fluorophores and coated with antibodies against the different target peptides. Next, biotin-conjugated antibodies against a second target epitope were added, which were labeled by adding streptavidin-conjugated phycoerythrin (PE). The microspheres were separately analyzed by flow cytometry on a Bio-Plex System (Bio-Rad, Hercules, CA). A 635-nm laser allowed microsphere classification based on the specific ratio of the two embedded fluorophores emitting light at different wavelengths and doublet discrimination; a 532-nm laser allowed quantification of the bound PE. Standard curves were generated for each analyte, and the median fluorescence intensity data were evaluated with a 5-parameter logistic curve-fitting method for calculating target concentrations in samples. Thirteen multiplexed immunoassays were included for the initial screening of medium conditioned by myotubes: IL-6, IL-7, IL-8, IL-13, IL-1␤, IL-2, IL-4, IL-5, IL-10, IL-12 (p70), IFN-␥, granulocyte macrophage colonystimulating factor (GM-CSF), and TNF-␣; only the first four assays gave results above the detection limit (0.13 pg/ml). Samples were tested in duplicate or triplicate.
Analysis of protein by Western blotting. Lysates of muscle cells cultured in 75-cm 2 flasks were prepared by adding PBS (SigmaAldrich) containing 1% Triton X-100 (Sigma-Aldrich) and Complete protease inhibitor cocktail (Roche, Mannheim, Germany) and stored at Ϫ70°C. Total protein concentrations of the lysates were determined with Uptima BC Assay reagents (Interchim, Montluçon cedex, France), and 30 g of protein was denatured in XT Sample Buffer under nonreducing or reducing (XT Reducing Agent) conditions by heating samples at 95°C for 5 min and subjected to SDS-PAGE using Criterion XT Bis-Tris 12% gel and XT MOPS Running Buffer, according to the manufacturer's protocol (Bio-Rad). Recombinant human (rh)IL-7 was loaded as a positive control (R&D Systems, Minneapolis, MN). Dual Color (catalog no. 161-0374, Bio-Rad) and Broad Range (catalog no. 161-0318, Bio-Rad) ladders were loaded as molecular weight standards. After electrophoresis the proteins were electroblotted onto activated 0.45-m Immobilon-P polyvinylidene fluoride membranes (Millipore), which were blocked overnight at 4°C in PBS with 5% skim milk (Fluka, Sigma-Aldrich) and 0.2% Tween 20 (Promega, Madison, WI). Immunodetection of IL-7 was performed at room temperature by incubating the blots in PBS containing 0.2% Tween (PBST) with the following additions: 1) rabbit anti-IL-7 polyclonal antibody (PAb) (catalog no. sc-7921, Santa Cruz Biotechnology, Santa Cruz, CA) diluted 1:200 and 1% skim milk for 1 h, followed by four PBST washes; 2) goat anti-rabbit IgG (heavy and light chain)-horseradish peroxidase mouse/human absorbed antibodies diluted 1:50,000 for 1 h (Southern Biotechnology, Birmingham, AL), followed by four final PBST washes. Proteins were visualized on Amersham Hyperfilm with the ECLϩ chemiluminescence kit (GE Healthcare Bio-Sciences, Piscataway, NJ).
Relative quantification of mRNA by real-time RT-PCR. Total RNA was isolated from human myotubes with the RNeasy Mini Kit (Qiagen, Hilden, Germany) and from murine myotubes with an ABI PRISM 6100 Nucleic Acid PrepStation (Applied Biosystems, Foster City, CA) according to the manufacturers' protocols and stored at Ϫ70°C. From skeletal muscle biopsies obtained in vivo, total RNA was isolated based on a modified version of the single-step method described by Chomczynski and Sacchi (see Ref. 15) . Real-time RT-PCR was performed with reagents and instruments from Applied Biosystems. Samples from in vitro experiments were analyzed in a 96-well format, whereas biopsies from the in vivo experiment were analyzed in a custom-made 384-well microfluidic card format. Up to 1 g total RNA was reverse transcribed into cDNA in 20-l reactions on a GeneAmp PCR 9700 thermal cycler with the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). The cDNA reactions were diluted with water before analyses, and an equivalent of 15-25 ng or 2.6 ng of RNA was analyzed in each well with the 96-or 384-well format, respectively. For the 96-well format, duplicate PCR reactions were set up containing diluted cDNA template (10 l), TaqMan Gene Expression Master Mix (12.5 l), and different predeveloped TaqMan Gene Expression Assays (1.25 l) and adjusted to a final volume of 25 l with water. The reaction mix and loading of the 384-well microfluidic cards were done according to the producer's instructions. The predeveloped assays all included a primer pair targeting separate exons and an intronspanning TaqMan probe, which was 6-carboxyfluorescein phosphoramidite (FAM) labeled in the 5= end and contained a minor groove binder and nonfluorescent quencher at the 3= end. We monitored the following human target genes (official gene symbol in parenthesis): interleukin-6 (IL6), Hs00174131_m1; interleukin-7 (IL7), Hs00174202_m1; interleukin-7 receptor ␣-chain (IL-7R), Hs00904814_m1; myogenic differentiation 1 (MYOD1), Hs00159528_m1; paired box 7 (PAX7), Hs00242962_m1; myogenin (MYOG), Hs00231167_m1; myosin heavy chain 2 (MYH2), Hs00430042_m1; desmin (DES), 01090875_m1. A predeveloped endogenous control assay targeting human large ribosomal protein P0 (RPLP0; catalog no. 4333761) was used to control for RNA loading and reverse transcription efficiency. Murine target genes were measured with the following assay: interleukin-7 (Il7) Mm00434291_m1. Realtime PCR was performed in a 7900HT Fast instrument with SDS 2.3 software and the default thermal cycling program: 10 min at 95°C initially to activate the enzyme, followed by 15 s at 95°C and 1 min at 60°C for 40 cycles (Applied Biosystems). Fluorescence acquisitions were made in real time at the end of each cycle and were analyzed with RQ manager software. Briefly, data were curve fitted, and the theoretical cycle number values (Ct) associated with fluorescence signals exceeding software-determined threshold levels were calculated on this basis. Tissue analyses yielding target fluorescence signals below the threshold levels were assigned a fixed Ct value of 40 and included for nonparametric statistical testing. Relative target mRNA expression levels were calculated as
, thereby normalizing the data to endogenous control RPLP0.
Indirect immunofluorescence. Satellite cells were differentiated to myotubes as described above, in ECM-coated four-or eight-well Lab-Tek Chamber Slides (Thermo Fisher Scientific, Roskilde, Denmark). After 7 days in culture, the cells were incubated for 18 h in the absence or presence of 1 g/ml of both LPS and BFA (SigmaAldrich). The cells were washed with PBS and fixed 15 min with 3% paraformaldehyde (Merck, Whitehouse Station, NJ) at pH 7.2-7.6, washed with PBS, and permeabilized for 15 min with 0.1% Triton X-100, followed by washing twice for 5 min with PBST (with 0.01% Tween 20) . The cells were blocked with PBST containing 2% BSA (PBST-BSA; Sigma-Aldrich) for 15 min. Primary antibodies were diluted in PBST-BSA: rabbit anti-IL-6 IgG PAb 1:20 (catalog no. sc-7920, Santa Cruz Biotechnology) or rabbit anti-IL-7 IgG PAb 1:20 (catalog no. sc-7921, Santa Cruz Biotechnology), together with mouse anti-myosin heavy chain IgG1 MAb, reactive toward human skeletal muscle type II fiber isoforms (1:100; catalog no. M-1570, SigmaAldrich) or rabbit anti-desmin PAb (1:20; catalog no. D-8281, SigmaAldrich), and incubated for 30 min. The primary antibody was omitted in negative controls. Cells were then washed three times for 5 min with PBST-BSA before incubation with fluorochrome-conjugated secondary antibodies for 30 min; goat anti-mouse IgG1 ϩ Alexa Fluor 594 (catalog no. A21125, Invitrogen, Carlsbad, CA) and goat antirabbit IgG ϩ Alexa Fluor 488 (catalog no. A11008, Invitrogen) were both diluted 1:400 in PBST-BSA. Finally, cells were washed six times for 5 min each in PBST-BSA, and 0.5 g/ml Hoechst 33342 (SigmaAldrich) was added in the fourth wash for DNA staining. The slides were mounted with Menzel Glaser coverslips (Gerhard Menzel Glasbearbeitungswerk, Braunschweig, Germany) and Dako mounting medium (DakoCytomation, Glostrup, Denmark) and examined with an Olympus BX61 microscope with an F-VIEW digital camera (Olympus). Photos were acquired on the computer with analySIS (Soft Imaging System, Munster, Germany).
Cell proliferation assay. Satellite cells were counted manually in a Bürcker counting chamber after 72 h of incubation: the external supports of the chamber were moistened with distilled water, and the cover glass was gently pushed onto the counting chamber from the front; satellite cells were detached with trypsin and resuspended in SkGM, and 50% (vol/vol) Trypan blue was added; the cells were deposited with a pipette between the cover glass and the counting chamber base and placed under a microscope; and viable cells were counted in 3 E-squares (0.004 mm 3 ). Satellite cells were seeded at 5,000/cm 2 into ECM-coated 12-well plates with SkGM and allowed to attach for 24 h. The cells were cultured in 0.5 ml of growth medium M2 [DMEM (5.5 mM glucose) containing 2% FCS (vol/vol), 2 mM L-glutamine, 50 U/ml penicillin, 50 g/ml streptomycin (SigmaAldrich), and 2% Ultroser G (Pall-Biosepra, Cergy-St-Christophe, France)] supplemented with 20 l of radiolabeled thymidine ([methyl-14 C]thymidine, 50 mCi/mmol; American Radiolabeled Chemicals, St. Louis, MO), with or without 50 ng/ml rh IL-7 (R&D Systems), and harvested after 0, 24, 48, 72, or 96 h. Fresh IL-7 and radiolabeled thymidine were added every 24 h. In short, cells were harvested by the following steps: 1) discarding the medium and washing twice with 1 ml of PBS on ice; 2) washing twice with 1 ml of cold 5% trichloroacetic acid; 3) adding 0.5 ml of 0.2 M NaOH and allowing the cells to lysate; 4) homogenization by ultrasound; and 5) analysis of 0.4 ml of lysate with addition of 3 ml of Ultima Gold TX scintillation fluid (PerkinElmer, Waltham, MA). Cell-associated radioactivity was measured with a WinSpectral liquid scintillation counter (PerkinElmer).
Cell migration assay. Before staining, satellite cells were cultured in SkGM until confluence. CellTracker Green CMFDA dye (Invitrogen) was first dissolved to 10 mM in DMSO to make a stock solution. Cells were washed twice with PBS and incubated for 30 min with the dye solution at 10 M in DMEM, which then was replaced with DMEM only and incubated for another 30 min at 37°C. The stained cells were washed once with PBS and detached with trypsin. Approximately 3,200 cells in 300 l of DMEM supplemented with 1% FCS were placed in the top compartment of each BD Falcon FluoroBlok insert (BD Biosciences, San Jose, CA), whereas the bottom compartments contained DMEM supplemented with 10% FCS Ϯ 100 ng/ml rhIL-7 or 10 ng/ml recombinant human hepatocyte growth factor (rhHGF; R&D Systems). FluoroBlok Multiwell Inserts contain a light-opaque polyethylene terephthalate (PET) microporous membrane specifically designed to absorb fluorescence within the 490-to 700-nm range and will not let through light emitted by CellTracker Green (absorption max ϭ 492 nm, emission maximum ϭ 517 nm). Images of the cells that had migrated from the top compartment, through the membrane, and into the bottom compartment were taken at different time points from below at ϫ4 magnification, covering the central ϳ7% of the insert area, with a Nikon digital camera DXM 1200 mounted on an ECLIPSE TS100 fluorescence inverted microscope, equipped with a mercury illuminator and ACT-1 software (Nikon, Tokyo, Japan). Cell counts were performed by image analyses with Kodak D1 3.6 software (Eastman Kodak, Rochester, NY), which was verified by blinded manual counting. A lactate dehydrogenase test (Cytotoxicity Detection Kit, Roche) was also performed to quantify cell damage or death.
Statistical analysis. Effect measures for in vitro experiments are reported as means Ϯ SE. Statistical differences were tested with SPSS 15 software, and P values Յ0.05 were considered significant. Effects of two different conditions on one dependent variable were tested with unpaired Student's t-tests. Effects of an independent variable with more than two levels (e.g., different time points) were tested with one-way ANOVA. Interaction effects of two independent variables (e.g., different incubation conditions) were tested with two-way ANOVA: major effects were explored whenever the interaction was not statistically significant; differences were further tested by separate one-way ANOVAs whenever there was a statistically significant interaction. Effects on more than one dependent variable were tested with multivariate ANOVA. Dunnett's test was used post hoc for multiple pairwise comparisons to baseline in time series experiments. Furthermore, the Benjamini-Hochberg method was applied to correct for multiple testing when comparing different dependent variables. Because of the lack of normal distribution revealed by a Kolmogorov-Smirnov test, in vivo data were tested nonparametrically with the Friedmann test and post hoc Wilcoxon signed-rank test.
RESULTS
IL-7 was detected at concentrations between 0.1 and 2 pg/ml in media conditioned by cultured human myotubes in a screen for unidentified myokines (see MATERIALS AND METHODS). This is a novel observation, and the concentrations were within the range observed in plasma samples from normal individuals (12) . In addition to IL-7, detectable levels of IL-6, IL-8, and IL-13 were observed to be released from the myotubes in line with previous reports (2, 19, 41) .
The concentration of IL-7 in the culture medium of differentiated human myotubes increased in a time-dependent manner, peaking at 2.0 pg/ml after 40 min of incubation (Fig. 1A) . Incubating the myotubes with BFA, an inhibitor of protein trafficking in the endomembrane system, did not alter levels of IL-7 accumulating in the medium (Fig. 1A) . A two-way ANOVA indicated that there was no interaction effect between incubation time and BFA impacting on IL-7 concentration (P ϭ 0.754), whereas there was a significant main effect of incubation time (P Ͻ 0.001). IL-6 concentrations were also monitored and determined to increase in a time-dependent manner, but, unlike IL-7, IL-6 levels were repressed by BFA (Fig. 1A) . Accordingly, an interaction effect between incubation time and BFA was observed (P ϭ 0.007), and follow-up one-way ANOVA showed that both incubation time (P ϭ 0.043) and BFA (P ϭ 0.049) affected IL-6 concentrations. Initially, IL-7 accumulated in the medium at a higher rate compared with IL-6 (Fig. 1) , and this was also supported by one-way multivariate ANOVA indicating an overall difference between these two interleukins (P Ͻ 0.001). To ascertain that IL-7 in the medium originated from the muscle cells, we quantified IL-7 mRNA expression in cultured muscle cell lysates by RT-PCR. In differentiated myotubes IL-7 mRNA was determined under basal conditions after 7 days of differentiation (mean C t ϭ 34.6 Ϯ 0.2, n ϭ 3 donors). The relative amount of IL-7 mRNA was 87% lower than the levels of mRNA transcribed from the IL-6 gene. In addition, a strong band with an apparent molecular mass of ϳ27 kDa, corresponding to glycosylated IL-7 (28), was detected in myotube lysates by Western blotting (Fig. 1B) . A faint immunoreactive band possibly representing 17-kDa nonglycosylated recombinant IL-7 was also detected (Fig. 1B) . To gain confidence that IL-7 expression is a trait of muscle cells in general, commonly used skeletal muscle cell lines were investigated. IL-7 mRNA expression was determined by RT-PCR (n ϭ 6) in murine C2C12 (C t ϭ 30.6 Ϯ 0.5) and Sol8 (C t ϭ 28.9 Ϯ 0.2) cells. These findings suggest that the IL-7 gene is expressed as mRNA and that IL-7 protein is synthesized and secreted from cultured muscle cells.
Myogenic differentiation increases IL-7. To determine whether IL-7 expression was specifically associated with differentiated muscle cells, expression was monitored during cell differentiation. ANOVA revealed that IL-7 mRNA expression tended to increase steadily as the cultures of satellite cells differentiated into myotubes (P ϭ 0.076), and post hoc comparisons showed that levels were significantly increased 3.5-fold above baseline after 7 days (Fig. 2A) . Apparently, cellassociated IL-7 protein levels also increased during differentiation ( Fig. 2A) . By contrast, IL-6 mRNA expression was unchanged during myogenesis (P ϭ 0.661; Fig. 2B ). Expression of skeletal muscle marker genes such as myogenic differentiation 1 (P ϭ 0.057), desmin (P ϭ 0.082), myogenin (P ϭ 0.073), and myosin heavy chain 2 (P ϭ 0.019) changed or tended to change during the differentiation of satellite cells into myotubes, whereas the satellite cell marker gene PAX7 (P ϭ 0.833) was unaltered. Post hoc comparisons showed that several myogenic marker genes were significantly enhanced at specific stages of myogenesis (Fig. 2, C and D) . Thus differentiation of human satellite cells into myotubes in vitro is associated with increased expression of IL-7 mRNA.
LPS enhances expression of IL-7 mRNA. The toll-like receptor-4 ligand LPS might regulate IL-7 production (38). IL-7 mRNA levels increased ninefold in human myotubes incubated with LPS compared with control (Fig. 3A) . However, when release and intracellular levels of IL-7 protein were investigated, these were rather unaffected by LPS (Fig. 3B) . LPS also increased IL-6 mRNA expression (Fig. 3A) and secretion (the latter was not statistically significant because of large variation in increase among donor cells; data not shown).
Primary cultures of differentiated myotubes may contain other cells as well; thus immunofluorescence microscopy was applied to determine whether myotubes express IL-7. Myotubes were incubated with or without LPS and BFA to enhance expression and possibly retention of IL-7 in the endomembrane system and optimize the detection conditions. In cultures of 2 . Enhanced IL-7 expression during myogenesis. Satellite cells were harvested at different time points during differentiation into myotubes: 1 day before (day Ϫ1) and different numbers of days after (days 1-7) the initiation (day 0) of differentiation. A: expression of IL-7 was determined at the mRNA level by RT-PCR and at the protein level by Western detection of intracellular IL-7 (7.5 g total protein) at days 0, 1, 6, or 7 (inset). B-D: expression of myogenic marker genes was determined by RT-PCR: IL-6 (B); myogenic differentiation 1 (MYOD1) and paired box 7 (PAX7) (C); myogenin (MYOG), desmin (DES), and myosin heavy chain 2 (MYH2) (D). RT-PCR data were relative to large ribosomal protein P0 (RPLP0), normalized to day Ϫ1, and each point represents mean Ϯ SE from 3 separate donors. A log scale is used in D. *P Յ 0.05 in post hoc comparisons relative to day Ϫ1. differentiated myotubes immunoreactive IL-7 appeared to be localized within striated and multinucleated myotubes also expressing myosin heavy chain, which is specifically expressed at late stages of muscle cell development (Fig. 4A, top) . Cells left unstained by IL-7 antibody showed lower signal intensity with the same filters and exposure times (Fig. 4A, bottom) . Addition of LPS and BFA to the incubation medium increased the intracellular protein levels of IL-7, mainly in the perinuclear region (Fig. 4A) . Because LPS and BFA incubations enhanced the intensity of the signal, it was possible to attribute IL-7 to the myotubes with high degree of reliability. Under these conditions, both IL-7 and IL-6 appeared to be localized in granules within striated and multinucleated myotubes also expressing myosin (Fig. 4B) . Once it had been established that IL-7 expression could be found in myotubes, efforts were made to localize it intracellularly in the basal state, without LPS and BFA. Under typical differentiation conditions IL-7 was observed in the lamellipodia at the polar end of myotubes coexpressing the intermediate myogenic marker desmin (Fig. 4C) .
Potential functions of IL-7. To investigate whether IL-7 might have a paracrine function within skeletal muscle, IL-7R mRNA expression levels were monitored during the course of satellite cell differentiation. One-way ANOVA revealed that IL-7R mRNA expression decreased significantly during differentiation to myotubes (P ϭ 0.010) to Ͻ20% of the initial level (Fig. 5A) . The effect of IL-7 on myogenesis was examined by differentiating satellite cells for 7 days in the absence or presence of recombinant IL-7. The degree of differentiation was then assessed by measuring expression of myogenic marker genes. Recombinant myostatin can inhibit myogenesis (24) and was used as a positive control. Compared with control, myotube marker MYH2 mRNA expression was reduced by 37% and 41% in cells incubated with recombinant IL-7 and myostatin, respectively (Fig. 5B) . Similarly, MYOG mRNA levels were reduced by 32% (P Ͻ 0.001) and 37% (P ϭ 0.007) with IL-7 and myostatin, respectively (n ϭ 6). On the other hand, the satellite cell marker PAX7 mRNA was increased by 23% and 104% after differentiation in the presence of recombinant IL-7 and myostatin, respectively (Fig.  5B) . Muscle cells incubated with recombinant IL-7 also displayed 42% reduction of IL-7 mRNA levels after 7 days of differentiation (Fig. 5B) . Recombinant myostatin tended to increase IL-7 mRNA expression by 42% (P ϭ 0.089). Thus, during development, IL-7 and myostatin have similar as well as different impacts on myotube gene expression.
Furthermore, we examined the effect of recombinant IL-7 on satellite cell proliferation by counting live cells after incubation with IL-7. Supplementation with 50 ng/ml recombinant IL-7 for 72 h increased the cell number by 23 Ϯ 8% (means Ϯ SE) compared with control (tendency; P ϭ 0.053, n ϭ 3). Next, we examined effects of IL-7 on cell proliferation in more detail by monitoring the incorporation of radiolabeled thymidine. Similar and linear satellite cell proliferation was observed for 96 h with or without recombinant IL-7 (Fig. 6A) . Incubation of satellite cells with recombinant IL-7 for 24 -96 h increased cell lysate protein levels ϳ7-11% above control (Fig. 6B) . HGF may inhibit cell differentiation (8) . In addition, HGF and other soluble factors have been shown to influence satellite cell migration (4, 5) . This led us to hypothesize that IL-7 inhibits satellite cell differentiation by altering cell migration. In a Transwell system, the presence of IL-7 increased satellite cell migration by 40 Ϯ 13% after 48 h, whereas no effect was observed after 24 h (Fig. 6, C and D) . The positive control, HGF, increased migration by 50 Ϯ 14% and 128 Ϯ 26% in satellite cells after 24 and 48 h, respectively (Fig. 6, C and D) . These data suggest that IL-7 may stimulate satellite cell migration.
Expression of IL-7 mRNA in human muscle biopsies. To evaluate the physiological role of IL-7 in vivo we monitored IL-7 mRNA by quantitative RT-PCR in musculus vastus lateralis and musculus trapezius of subjects undergoing strength training up to 2 and 11 wk. Relative IL-7 expression levels at baseline were ϳ10-fold higher in trapezius than in vastus lateralis (Fig. 7) . There was a significant difference in vastus lateralis IL-7 mRNA levels across the three time points, as indicated by the Friedman test (P ϭ 0.045). Compared with baseline, mean relative mRNA expression levels of IL-7 were enhanced threefold after 11 wk of training (Fig. 7A) but not significantly after 2 wk (P ϭ 0.139). Similarly, trapezius IL-7 expression was different across time (P ϭ 0.050); compared with baseline IL-7 increased twofold after 2 wk and fourfold after 11 wk of training (Fig. 7B ). IL-6 mRNA expression, on the other hand, was not significantly affected by strength training (Fig. 7) , when inspected with the Friedman test (vastus lateralis P ϭ 0.407 and trapezius P ϭ 0.867).
DISCUSSION
It has been shown previously that IL-7 is produced in stromal cells in lymphoid organs and a few other human cell types such as intestinal epithelial cells (20, 30, 44) . To our knowledge, this is the first report on the expression and secretion of IL-7 in skeletal muscle cells. IL-7 was secreted by differentiated human skeletal muscle cells in primary culture, and medium concentrations increased in a time-dependent fashion. The IL-7 gene was expressed in human myotubes at the level of mRNA and protein. In addition, two murine cell lines differentiated into myotubes also expressed IL-7 mRNA. Two lines of in vitro evidence indicate that IL-7 secreted from human muscle cells originates specifically from the fully differentiated multinucleated myotubes: 1) IL-7 mRNA and pro- Fig. 3 . Differential effects of LPS on IL-7 mRNA and protein expression in myotubes. A: human myotubes differentiated for 7 days were incubated Ϯ LPS (1 g/ml) for 6 h, relative IL-7 mRNA expression levels were determined by real-time RT-PCR, and data are presented as fold change relative to control (Ϫ). B: similarly, myotubes were incubated Ϯ LPS, IL-7 concentrations in the media were determined by immunoassay, and intracellular IL-7 was determined by Western blotting (inset). Data from 3 donors are presented as means Ϯ SE. *P Յ 0.001, Student's t-tests.
tein levels increase during differentiation of satellite cells into myotubes in concert with several myogenic marker genes, and 2) multinucleated cells coexpress IL-7 and myosin heavy chain, visualized in immunofluorescent microscopic images of myotubes in the basal state and stimulated by LPS plus BFA. We also present in vivo data indicating that the human IL-7 gene is expressed in skeletal muscle tissue. The IL-7 mRNA level in human skeletal muscle is low but comparable to the well-established myokine IL-6. Skeletal muscle comprises as much as 40 -50% of the adult human body mass. Consequently, given its large mass compared with other tissues, skeletal muscle is potentially a major source of circulating IL-7. After establishing that IL-7 is expressed by skeletal muscle cells, we investigated regulation of IL-7 in skeletal muscle cells both in vitro and in vivo, seeking to elucidate its relevance in muscle physiology.
First, we studied IL-7 secretion and expression in vitro. Secretion of IL-7 was rapid; concentrations in cultures of skeletal muscle cells peaked within the first hour of incubation and then leveled out. IL-7 levels were not affected by BFA, an inhibitor of cellular protein secretion. Thus the initial secretion of IL-7 protein may take place via a secretory pathway independent of the membranotubular network. On the basis of our data, one may speculate that IL-7 is preformed and stored in post-Golgi secretory vesicles. Indeed, this is in agreement with immunofluorescent microscopic images of IL-7 in granules lining the lamellipodia of myotubes in the basal state. This aspect was further enlightened by some discrepancies in our assessments of IL-7 expression in relation to LPS and BFA. In line with the lack of effect of BFA on IL-7 secretion, we observed that LPS increased mRNA expression but had no effects on secretion and intracellular protein levels. This suggests that in skeletal muscle cells regulation of IL-7 gene expression might be separated from its total protein levels and secretion. However, the combination of LPS and BFA increased immunofluorescence signal from IL-7 probably de- Fig. 4 . Intracellular IL-7 in multinucleated myotubes expressing myosin heavy chain. A: human myotubes differentiated for 7 days on slides were incubated for 18 h Ϯ LPS (1 g/ml) and BFA (1 g/ml) and stained with (a and b) or without (c and d) IL-7 antibody (800-ms exposures); with myosin heavy chain antibody (Myh; 100-ms exposures; e-h); and with Hoechst 33342 (DNA, 50-ms exposures; i-l). Images were merged (m-p) to evaluate coexpression of IL-7 and myosin heavy chain protein. B: immunodetection (both green) of IL-7 (q) or IL-6 (r) together with myosin heavy chain (red) and DNA staining (blue) in myotubes incubated Ϯ LPS (1 g/ml) and BFA (1 g/ml). IL-7 and IL-6 (arrows) localize to multinucleated myosin heavy chain-expressing myotubes. C: immunodetection of IL-7 (red) and desmin (green) in unstimulated myotubes (s and t). IL-7 localizes to lamellipodia (arrows) of desmin-expressing myotubes. Representative images from 3 experiments using different cell donors are shown. tained in the endoplasmic reticulum. BFA affects the location of IL-7 intracellularly but not its secretion, which might suggest that IL-7 is recycled between the Golgi apparatus and secretory vesicles in the basal state. So far we have not identified conditions or mechanisms resulting in high levels of IL-7 secretion. Given previous data suggesting that IL-7 secretion is inert to LPS in intestinal epithelial cells (50) , one might speculate that secretion of IL-7 is regulated similarly in other cell types as well. Then again, in some cell types there seems to be coordinated protein secretion and mRNA expression of IL-7 (30, 44) , suggesting that the regulation is cell-and tissue specific. In our present study, we describe IL-7 secretion by skeletal muscle cells based on measurements of its concentrations in conditioned culture media. Because these IL-7 levels might not be due to secretion alone but potentially protein instability, degradation, and cellular reuptake as well, care should be taken not to draw firm conclusions regarding the dynamics of IL-7 secretion. It should be noted that degradation rather than production has been brought forward as the main mechanism regulating extracellular IL-7 levels (23). Future studies should address the detailed events of IL-7 secretion and factors affecting its half-life.
We also investigated potential regulation of IL-7 in vivo. The effect of training on IL-7 mRNA in skeletal muscle was monitored in individuals on a strength training program after 2 and 11 wk. The results indicate that IL-7 mRNA is enhanced after 2 wk of training. To our knowledge there is only one previous study monitoring the short-term effect of training on plasma IL-7 level (3). Immediately after a 90-min soccer game, elite female soccer players displayed a significantly elevated plasma concentration of IL-7. However, when a second game was played, 72 h after the first game, the IL-7 concentration was nonsignificantly increased. Few studies are available on the myokine response during and shortly after exercise, although calprotectin (23) , , and IL-6 (39) may be regulated acutely. We observed no effect of training on IL-6 mRNA levels, and this finding is in line with the unchanged plasma IL-6 levels reported after 12 wk of endurance training (10) . There are only a few long-term studies involving skeletal muscle biopsy material, and evidence is limited as to whether the exercise-induced increase of IL-6 is affected by training (33) . In one study of patients with chronic obstructive pulmonary disease, 10 wk of exercise did not alter skeletal muscle mRNA levels of IL-6 and TNF-␣ (47), and there have been reports of increased levels of skeletal muscle mRNA encoding IL-4 and IL-13 (34) . In rats, 7 wk of exercise either increased or reduced IL-1ra, IL-1␤, and IL-12 protein levels in skeletal muscle and adipose tissue, respectively, whereas IL-6 protein expression remained unchanged (16) . Our present study is not suited to separating long-and short-term effects of training, and thus additional studies of IL-7 in the short term should be done. Furthermore, investigations of plasma concentrations are also warranted to establish this myokine as exercise responsive.
So far, our in vitro and in vivo data indicate that IL-7 expression is regulated in muscle cells, supporting the notion that this myokine may serve a physiological function. It is possible that IL-7 secreted from skeletal muscle represents an endocrine link between skeletal muscle and lymphocytes of the immune system (39). We have not investigated effects of muscle exercise on plasma levels of IL-7, but this will be addressed in ongoing studies. On the other hand, our initial investigations showed that IL-7R expression is enhanced in undifferentiated satellite cells, suggesting that IL-7 signaling might be of importance at this developmental stage. When satellite cells differentiated in the presence of recombinant IL-7, the myotube phenotype was altered, manifested by reduced mRNA expression of the terminal differentiation marker MYH2. In line with previous in vitro studies showing that myostatin acts by inhibiting the myogenic differentiation of myoblasts (22, 35) , we observed that recombinant myostatin had a negative effect on MYH2 gene expression in differentiating human muscle cells. The expression of the satellite cell marker gene PAX7 was elevated in cells incubated with IL-7 or myostatin during differentiation. Thus IL-7 and myostatin may both alter certain aspects of myogenic differentiation, whereas their mechanisms of action are unknown and are likely to differ. Also, IL-7 mRNA expression was reduced by recombinant IL-7 during the differentiation, whereas it is unclear whether this is due to a direct effect on IL-7 gene transcription or an inhibition of terminal differentiation.
Because our data suggested that differentiation was inhibited, we investigated whether IL-7 could direct satellite cells toward alternative developmental routes. Myogenesis not only depends on initiation of muscle-specific gene expression but also requires arrest of satellite cell proliferation. Satellite cell replication is initiated in response to several cytokines and growth factors (7, 40) . Thus we hypothesized that recombinant IL-7 would enhance satellite cell proliferation at the expense of differentiation. However, no effect of IL-7 was seen on proliferation of satellite cells. HGF, which has been implicated as a chemoattractant for myogenic cells in the early embryo (6, 43) and satellite cells during muscle regeneration (4), may also delay cellular differentiation (26) . Thus we tested whether HGF and, similarly, IL-7 could promote satellite cell migration. In line with HGF, we observed that IL-7 enhanced satellite cell migration. Thus we propose that IL-7 may stimulate increased satellite cell migration and thereby indirectly contribute to reduced differentiation. Because IL-7 also tended to increase satellite cell numbers and intracellular protein levels, the possibility should be considered that IL-7 also might affect survival and exaggerate the effect seen on migration, but this has not been investigated thoroughly. It may seem contradictory that IL-7 mRNA is increased by training in vivo, whereas it inhibits myogenic development in vitro. The persons investigated here performed exercise of rather low intensity without generating significant amount of muscle damage. Still, the number of satellite cells progressively increased up to 40% in skeletal muscle biopsies throughout the training period (T. Raastad, unpublished observation). Thus a modest level of myogenic regeneration may have been induced. It is plausible that IL-7 inhibits terminal differentiation, allowing satellite cells to enter into a proliferative state under stimulus of additional mitotic factors.
IL-6 was used as an internal myokine control throughout this study. It is clear that IL-6 and IL-7 are expressed and regulated in quite different manners. For example, in accordance with a previous study (40), we could not detect altered mRNA expression of IL-6 during myogenesis, indicating that full differentiation is not necessary for secretion of IL-6. Still, we observed intracellular IL-6 in multinucleated myotubes expressing myosin heavy chain by immunofluorescence microscopy. It is therefore likely that muscle cells ubiquitously secrete IL-6 at different developmental stages, although this was not thoroughly examined in our present study. Also, our in vivo study suggests a discrepancy between these interleukins in muscle physiology. Importantly, our data confirming that IL-6 is produced by skeletal muscle cells serve to validate the utilization of our cell model for discovering novel myokines like IL-7.
In conclusion, our experiments indicate that IL-7 is a novel myokine, produced and secreted by differentiated human skeletal muscle cells. IL-7 affects myogenesis and migration, and its production is regulated both in vitro and in vivo, suggesting that muscular IL-7 has physiological importance. 
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